Skip to main content

Table 2 Baseline – RA-specific characteristics

From: Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study

  RA, DMARD (n = 10) RA, anti-TNF (n = 13) p value
ESR, mm/H 9 [7–21] 6 [6–17] 0.689
Disease activity score (DAS28) 2.24 [1.3–2.5] 1.98 [1.8–2.2] 1.000
Anti-CCP positive (%) 7 (70) 8 (61) 0.673
Rheumatoid factor positive (%) 8 (80) 7 (54) 0.192
Disease duration, years 7.8 [4.0–10.2] 13.3 [9.3–20.2] 0.012
Anti-TNF n/a   n/a
- Adalimumab   10  
- Certolizumab   1  
- Etanercept   1  
Disease duration until start anti-TNF, years 1.2 [1.0–1.7] 5.6 [4.3–9.1] 0.001
Anti-TNF withdrawal attempts, yes/no 10/0 9/4 n/a
DMARD    n/a
- Methotrexate 9 11  
- Sulfasalazine 1   
Other Rx    
- Statin 1 1 0.848
- Antihypertensive 5 5 0.580
  1. Values are n (%), mean ± SD or median [IQR,] for skewed data
  2. RA rheumatoid activity, DMARD disease-modifying antirheumatic drug, TNF tumor necrosis factor, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on 28 joints, CCP cyclic citrullinated peptide